Flemington, NJ, United States of America

Richard A Rampulla

USPTO Granted Patents = 6 

 

Average Co-Inventor Count = 16.1

ph-index = 2

Forward Citations = 12(Granted Patents)


Company Filing History:


Years Active: 2006-2014

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Richard A. Rampulla: Innovator in Heterocyclic CETP Inhibitors

Introduction

Richard A. Rampulla is a notable inventor based in Flemington, NJ (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of heterocyclic CETP inhibitors. With a total of 6 patents to his name, Rampulla's work has had a considerable impact on medical research and drug development.

Latest Patents

Among his latest patents are innovative compounds described as heterocyclic CETP inhibitors. These include compounds of formula Ia and Ib, wherein A, B, C, and R are detailed in the patent documentation. His research focuses on the potential therapeutic applications of these compounds in treating various health conditions.

Career Highlights

Richard A. Rampulla is currently employed at Bristol-Myers Squibb Company, a leading global biopharmaceutical company. His role involves extensive research and development, contributing to the advancement of new therapeutic solutions. His expertise in the field has positioned him as a key player in pharmaceutical innovation.

Collaborations

Throughout his career, Rampulla has collaborated with several esteemed colleagues, including Mark E. Salvati and Jacques Y. Roberge. These collaborations have fostered a productive environment for innovation and have led to the successful development of new pharmaceutical compounds.

Conclusion

Richard A. Rampulla's contributions to the field of pharmaceuticals, particularly through his patents on heterocyclic CETP inhibitors, highlight his role as a significant inventor. His work continues to influence the landscape of medical research and drug development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…